ArticleEuropean child & adolescent psychiatry2025
The use of atypical antipsychotic medications in the treatment of children and adolescents with avoidant/restrictive food intake disorder.
Article in European child & adolescent psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAvoidant restrictive food intake disorder (ARFID) is a childhood feeding and eating disorder often associated with marked physical and psychosocial impairment.
objectiveWe assessed the use of atypical antipsychotic (AAP) medications (mostly risperidone) in promoting weight and height gain in children with ARFID.
methodsThe computerized medical records of 21 children with ARFID receiving AAPs in one center in Israel were retrospectively reviewed. Fourteen children received AAPs after 6.30 ± 0.75 months of no weight gain with treatment as usual (either group or individual cognitive behavioral therapy); seven children were admitted to our clinic receiving AAPs in previous facilities because of lack of weight gain. All were followed-up for 18 months. Weight and height were extracted from the medial records at eight time points.
resultsA significant increase was found in weight, height, and body mass index (BMI) over 18 months of treatment with AAPs (Δweight: 9.66 ± 9.24 kg, p < 0.001; Δheight: 10.23 ± 11.54 cm, p < 0.001; ΔBMI = 2.55 ± 1.53 kg/m
conclusionThe addition of AAPs for a period of 18 months may be safe and effective in increasing weight and height in children with ARFID.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.